The Actinic Keratosis Treatment Toolbox: Prescription, Procedural, and Preventative Strategies
Following up on insights shared at the ODAC Dermatology Conference, Dr. Neal Bhatia, MD, FAAD, Director of Clinical Dermatology at Therapeutics Clinical Research, offered a comprehensive overview of actinic keratosis (AK) management. Dr. Bhatia emphasized actionable approaches to balancing prescription topicals and procedural techniques in everyday practice.
The incidence for non-melanoma skin …
Following up on insights shared at the ODAC Dermatology Conference, Dr. Neal Bhatia, MD, FAAD, Director of Clinical Dermatology at Therapeutics Clinical Research, offered a comprehensive overview of actinic keratosis (AK) management. Dr. Bhatia emphasized actionable approaches to balancing prescription topicals and procedural techniques in everyday practice.
The incidence for non-melanoma skin … 
As 2024 comes to a close, the Journal of Drugs in Dermatology delivers a stellar lineup of research, reviews, and insights to inform your practice and inspire your curiosity. This month's Editor's Picks feature cutting-edge studies and expert commentary on a range of topics, from advanced acne treatments to groundbreaking leadership initiatives in dermatology.
Laser and Energy Treatments for Ac … 
Cemiplimab is a monoclonal antibody therapy that has emerged as a promising treatment option for certain types of advanced skin cancer. Specifically designed to target the programmed cell death protein 1 (PD-1) pathway, cemiplimab works by blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2, thereby unleashing the body's immune system to recognize and attack cancer cells. We con … 
Don’t forget about intralesional therapy as a treatment option for cutaneous malignancies, including non-melanoma and melanoma skin cancers, says Dr. Vishal A. Patel, director of cutaneous oncology at the GW Cancer Center. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. Patel, who shared in which patients intralesional therapy may be … 
Basal cell carcinoma (BCC) is the most common human cancer. When curative surgery and radiotherapy are contraindicated, systemic agents targeting the hedgehog signaling pathway are invaluable options for this subset of adult patients with locally advanced BCC (laBCC). Vismodegib and sonidegib are oral options with similar efficacy and side effect profiles. With the absence of head-to-head comparis …